Abstract

The use of gentamicin was studied in 80 patients with cystic fibrosis complicated by severe chronic pulmonary infection due to Pseudomonas. Gentamicin was administered intramuscularly or intravenously in a dose of 7 mg/kg per 24 hr not exceeding a total daily dose of 180 mg. In some cases, 16–20 mg four times a day was administered by aerosol. Clinical, bacteriologic, hematologic, renal, hepatic, and pulmonary evaluations were carried out. Gentamicin was well tolerated and appears to be a relatively nontoxic drug when used at this dose. It was clinically effective in controlling severe pseudomonas pulmonary infection in patients with cystic fibrosis.

This content is only available as a PDF.
You do not currently have access to this article.